Patent ID: 11903997
Assignee: ORBSEN THERAPEUTICS LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 3:
4. The method of claim 1, further comprising administering at least one autoimmune disease agent selected from the group consisting of a non-steroidal anti-inflammatory drug (NSAID), ibuprofen, naproxen, meloxicam, etodolac, nabumetone, sulindac, tolementin, choline magnesium trisalicylate, diclofenac, diflusinal, indomethacin, ketoprofen, oxaprozin, piroxicam, celecoxib, etoricoxib, lumiracoxib, a corticosteroid, methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, a TNFa inhibitor, etanercept, adalimumab, infliximab, certolizumab pegol, golimumab, abatacept, rituximab, tociluzumab, anakinra, cyclosporine, antithymocyte globulin, mycophenolate mofetil, and cyclophosphamide.